Redhill Biopharma Ltd (RDHL) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Redhill Biopharma Ltd stock (RDHL) is currently trading at $0.89. Redhill Biopharma Ltd PS ratio (Price-to-Sales) is 0.47. Analyst consensus price target for RDHL is $19000.00. WallStSmart rates RDHL as Sell.
- RDHL PE ratio analysis and historical PE chart
- RDHL PS ratio (Price-to-Sales) history and trend
- RDHL intrinsic value — DCF, Graham Number, EPV models
- RDHL stock price prediction 2025 2026 2027 2028 2029 2030
- RDHL fair value vs current price
- RDHL insider transactions and insider buying
- Is RDHL undervalued or overvalued?
- Redhill Biopharma Ltd financial analysis — revenue, earnings, cash flow
- RDHL Piotroski F-Score and Altman Z-Score
- RDHL analyst price target and Smart Rating
Redhill Biopharma
📊 No data available
Try selecting a different time range
Smart Analysis
Redhill Biopharma Ltd (RDHL) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Redhill Biopharma Ltd (RDHL) Key Strengths (2)
Paying less than $1 for every $1 of annual revenue
Revenue surging 58.60% year-over-year
Supporting Valuation Data
Redhill Biopharma Ltd (RDHL) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 203.2x book value
Very low institutional interest at 9.77%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Redhill Biopharma Ltd (RDHL) Detailed Analysis Report
Overall Assessment
This company scores 29/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 1.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Revenue Growth. Valuation metrics including Price/Sales (0.47) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 58.60%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Book (203.21) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -1709.00%, Operating Margin at -107.30%, Profit Margin at -97.50%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -1709.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 58.60% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
RDHL Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
RDHL's Price-to-Sales ratio of 0.47x trades at a deep discount to its historical average of 759.45x (24th percentile). The current valuation is 100% below its historical high of 7433.26x set in Jun 2014, and 4610% above its historical low of 0.01x in Dec 2022. Over the past 12 months, the PS ratio has compressed from ~1.8x as trailing revenue scaled faster than the stock price.
Compare RDHL with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Redhill Biopharma Ltd (RDHL) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Redhill Biopharma Ltd is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 10M with 59% growth year-over-year. The company is currently unprofitable, posting a -97.5% profit margin.
Key Findings
Revenue growing at 59% YoY, reaching 10M. This pace significantly outperforms most DRUG MANUFACTURERS - SPECIALTY & GENERIC peers.
The company is unprofitable with a -97.5% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -3M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Redhill Biopharma Ltd maintain 59%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 4.99, so expect amplified moves relative to the broader market.
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Redhill Biopharma Ltd.
Bottom Line
Redhill Biopharma Ltd is a high-conviction growth story with revenue accelerating at 59% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -97.5% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 8:27:48 AM
About Redhill Biopharma Ltd(RDHL)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company is headquartered in Tel Aviv, Israel.